Rhenium (186Re) obisbemeda by Plus Therapeutics for Head And Neck Cancer: Likelihood of Approval
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Head And Neck Cancer.…
Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Head And Neck Cancer.…